Sio Gene Therapies Inc. Stock

SIOX

US8293991043

OTC Markets Traded

Latest news : Sio Gene Therapies Inc.

23-03-27	Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index	CI
23-03-22	Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index	CI
23-02-14	Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	CI
22-12-14	Sio Gene Therapies Board Approves Plan of Liquidation, Dissolution; Shares Rise After Hours	MT
22-11-10	Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	CI
22-08-11	Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	CI
22-06-20	Sio Gene Therapies Inc.(NasdaqGS:SIOX) dropped from S&P Global BMI Index	CI
22-06-14	Sio Gene Therapies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	CI
22-06-14	Sio Gene Therapies Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	CI
22-04-28	HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	MT
22-04-28	Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	MT
22-04-28	Top Premarket Decliners	MT
22-04-26	Sio Gene Therapies to Explore and Review A Range of Strategic Alternatives Focused on Maximizing Stockholder Value	CI

More news

Analysts' recommendations: Sio Gene Therapies Inc.

22-04-28	HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	MT
22-04-28	Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	MT
22-02-01	Cantor Adjusts Sio Gene Therapies Price Target to $3 From $8, Maintains Overweight Rating	MT
22-02-01	HC Wainwright Adjusts Price Target on Sio Gene Therapies to $7 From $10, Reiterates Buy Rating	MT
22-02-01	SVB Leerink Downgrades Sio Gene Therapies to Market Perform From Outperform, Adjusts Price Target to $1 From $6	MT

More recommendations

Press Releases: Sio Gene Therapies Inc.

24-02-02	Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	AQ
24-02-02	Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	GL
23-04-06	SIO GENE THERAPIES INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
23-03-15	Sio Gene Therapies : Failure to Satisfy Listing Rule - Form 8-K	PU
23-03-15	SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ

More press releases

Managers and Directors: Sio Gene Therapies Inc.

Manager	Title	Age	Since
David Nassif CEO	Chief Executive Officer	72	2022-01-30

Director	Title	Age	Since
David Nassif BRD	Director/Board Member	72	2022-01-30

More insiders

Sio Gene Therapies Inc. was a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The Company has not generated any revenue.

Employees

Sector

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/8/22	Parag V. Meswani	Free	Chief Operating Officer	153,700	0.2091%
2/8/22	David Nassif	Free	Chief Executive Officer	546,500	0.7437%
1/28/22	Parag V. Meswani	Other	Chief Operating Officer	368,799	0.5018%

Sio Gene Therapies Inc. Stock

Stocks

SIOX

US8293991043

Latest news : Sio Gene Therapies Inc.

Analysts' recommendations: Sio Gene Therapies Inc.

Press Releases: Sio Gene Therapies Inc.

Quotes and Performance

Managers and Directors: Sio Gene Therapies Inc.

Latest insider transactions

Company Profile